BioMeetingpoint at the Biotechnica

The Biotechnology Thematic Group (BioTG) of the IRC Network together with other European partners are organising again the BioMeetingpoint for companies, R&D organisations and stakeholders to hold bilateral meetings at Biotechnica Hannover, Europe's leading biotechnology trade fair, which will take place in Hannover, Germany 9 - 11 October 2007.

Since 1985 Biotechnica Hannover has been the most important trade show in Europe for biotechnology. For the BioMeetingpoint a catalogue of company profiles and technology offers and requests will be available electronically and will allow participating companies and organisations to organise their individual meetings in advance.

The BioMeetingpoint functions as an "interface between research and the private sector" allowing new technologies, processes, patents and licenses to be offered and experience in financing, production, marketing and distribution to be requested, thus bringing compatible partners together.

The BioMeetingpoint is the ideal environment for:

  • Enterprises offering and/or using innovative technologies.
  • Enterprises that are looking for expertise and know-how in the areas of production, marketing and distribution or wish to provide this knowledge to others.
  • Scientists and research institutes offering application-oriented research results.
  • Start-ups.
  • Investors.

They will have the opportunity to get to know selected partners during individual discussions, which aim to pave the way for future co-operations.

For further information, please visit:
http://www.biomeetingpoint.org

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

How old antibiotic compounds could become tomorrow…

As the fight against drug-resistant infections continues, University of Leeds scientists are looking back at previously discarded chemical compounds, to see if any could ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]